RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 Hepatitis C: The Impact of New and Future Therapeutics
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 14
SP 32
OP 33
DO 10.1177/155989771214016
UL http://mdc.sagepub.com/content/12/14/32.abstract
AB The burden of hepatitis C (HCV) in the United States now exceeds that of HIV and hepatitis B combined. It is estimated that from 2010 to 2019, 193,000 HCV-related deaths, direct medical care costs of $10.7 billion, and $75.3 billion in societal costs can be expected. HCV-associated liver related morbidity and mortality is an important component of this burden [Wong JB et al. Am J Public Health 2000]. This article discusses how antiviral therapy targeted to achieve viral eradication is the key strategy to stabilizing or reversing liver injury and fibrosis, and reducing the risk of liver-related complications, including cirrhosis and liver cancer, in patients with HCV.